NASDAQ : DNTH
Dianthus Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 82.38 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.61B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.60B |
| Enterprise Value | 3.41B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 55.93M |
| Shares Outstanding | 55.93M |
| Shares Change (YoY) | +32.34% |
| Shares Change (QoQ) | +16.65% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 125.54% |
| Float | 55.85M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,416.28 |
| Forward PS | 3,105.20 |
| PB Ratio | 3.85 |
| P/TBV Ratio | 3.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1,791.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 26.10 |
| Quick Ratio | 25.79 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -26.07% |
| Return on Assets (ROA) | -17.69% |
| Return on Invested Capital (ROIC) | -18.43% |
| Return on Capital Employed (ROCE) | -18.48% |
| Weighted Average Cost of Capital (WACC) | 5.24% |
| Revenue Per Employee | $20,696 |
| Profits Per Employee | -$2.09M |
| Employee Count | 92 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +135.13% |
| 50-Day Moving Average | 92.18 |
| 200-Day Moving Average | 85.22 |
| Relative Strength Index (RSI) | 46.49 |
| Average Volume (20 Days) | 938,997 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.99M |
| Short Previous Month | 9.14M |
| Short % of Shares Out | 16.07% |
| Short % of Float | 16.09% |
| Short Ratio (days to cover) | 9.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.90M |
| Gross Profit | 1.90M |
| Operating Income | -217.84M |
| Pretax Income | -192.25M |
| Net Income | -192.25M |
| EBITDA | -217.72M |
| EBIT | -217.84M |
| Loss Per Share | -$4.11 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 886.81M |
| Total Debt | 1.29M |
| Net Cash | 1.19B |
| Net Cash Per Share | $21.26 |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 21.39 |
| Working Capital | 863.15M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -155.38M |
| Capital Expenditures | -334,000 |
| Depreciation & Amortization | 123,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -155.71M |
| FCF Per Share | -$2.78 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -11,441.39% |
| Pretax Margin | -10,096.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -32.34% |
| Shareholder Yield | -32.34% |
| Earnings Yield | -5.00% |
| FCF Yield | -3.38% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $139.06 |
| Price Target Difference | 69.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 63.23% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 35.67 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |